

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 823 429 A1

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

11.02.1998 Bulletin 1998/07

(51) Int. Cl.<sup>6</sup>: **C07D 313/00**, C07D 493/04,  
A61K 31/365

(21) Application number: 96912263.9

(86) International application number:

PCT/JP96/01158

(22) Date of filing: 26.04.1996

(87) International publication number:

WO 96/33989 (31.10.1996 Gazette 1996/48)

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE

(30) Priority: 26.04.1995 JP 102626/95

(71) Applicant:

Kyowa Hakko Kogyo Co., Ltd.  
Chiyoda-ku, Tokyo 100 (JP)

(72) Inventors:

- AGATSUMA, Tsutomu  
Tokyo 194 (JP)
- SAITOH, Yutaka  
Tokyo 194 (JP)
- YAMASHITA, Yoshinori  
Tokyo 194 (JP)

• MIZUKAMI, Tamio

Tokyo 194 (JP)

• AKINAGA, Shiro

Shizuoka 411 (JP)

• GOMI, Katsushige

Shizuoka 410-11 (JP)

• AKASAKA, Kazuhito

Shizuoka 411 (JP)

• TAKAHASHI, Isami

Tokyo 206 (JP)

(74) Representative:

Casalunga, Axel et al


BUREAU D.A. CASALONGA - JOSSE

Morassistrasse 8

80469 München (DE)

(54) **RADICICOL DERIVATIVES**

(57) The present invention relates to radicicol derivatives represented by the following formula (I) or pharmacologically acceptable salts thereof:



(I)

wherein R<sup>1</sup> and R<sup>2</sup> are the same or different and each represents hydrogen, alkanoyl, alkenoyl or tert-butyldimethylsilyl; (1) when X represents halogen, Y represents an oxygen atom or R<sup>4</sup>-O-N (wherein R<sup>4</sup> represents hydrogen or substituted or unsubstituted lower alkyl); and R<sup>3</sup> represents hydrogen, alkanoyl, alkenoyl or the like; and (2) when X and R<sup>3</sup> are combined with each other to represent a single bond; Y represents R<sup>4B</sup>-O-N (wherein R<sup>4B</sup> has the same meaning as R<sup>4</sup>). The radicicol derivatives of the present invention demonstrate tyrosine kinase inhibition activity and pharmacological activities such as antitumor, antimicrobial or immunosuppression effects.

Best Available Copy


## Description

## TECHNICAL FIELD

The present invention relates to novel radicicol derivatives or pharmacologically acceptable salts thereof which show tyrosine kinase inhibition activity and have antitumor, antimicrobial or immunosuppression effects.

## BACKGROUND ART

It is known that microbial metabolite radicicol represented by the following formula (B) has an antifungal effect and an anticancer effect [*Nature*, 171, 344 (1953); *Neoplasma*, 24, 21 (1977)] or an immunosuppression effect (Japanese Published Unexamined Patent Application No. 298764/94).



Furthermore, it is known that radicicol derivatives in which the phenolic hydroxyl group is modified with various acyl groups have an antitumor effect (Japanese Published Unexamined Patent Application No. 226991/92). In addition, it is disclosed that radicicol derivatives in which the phenolic hydroxyl group is modified with an acyl group or an alkyl group show an angiogenesis inhibition effect (Japanese Published Unexamined Patent Application No. 279279/94).

Tyrosine kinase is an enzyme which uses ATP as a phosphate donor and catalyzes transfer of its  $\gamma$ -phosphate group to the hydroxyl group of a specified tyrosine residue of a substrate protein, thereby taking an important role in the control mechanism of intracellular signal transduction. Various tyrosine kinase families are known, and it is known that tyrosine kinase activities (e.g., Src in colon cancer, ErbB-2 in breast cancer and gastric cancer, Abb in leukemia, and the like) increase. Disordered increase in the tyrosine kinase activity causes abnormal differentiation and proliferation of cells. In consequence, specific inhibitors of tyrosine kinase are useful in preventing and treating various diseases, including as antitumor agents.


Lck is a tyrosine kinase which is activated when T lymphocytes are activated by antigen stimulation, and an inhibitor of this enzyme is useful as an immunosuppressant. Also, it is known that Src is concerned in bone resorption in osteoclast, and an inhibitor of this tyrosine kinase is useful as a bone resorption inhibitor for the treatment of osteoporosis. In addition, inhibitors of EGF-R (epidermal growth factor receptor), FGF-R (fibroblast growth factor receptor), PDGF-R (platelet-derived growth factor receptor) and the like as receptor type tyrosine kinases of various growth factors are useful as a solid cancer growth inhibitor, an angiogenesis inhibitor, a vascular smooth muscle growth inhibitor and the like.

The inhibitory effect of the tyrosine kinase activity can be measured by carrying out Western blotting analysis with an anti-phosphotyrosine antibody using a rat fibroblast cell strain SR-3Y1 transformed with an oncogene v-Src (available from RIKEN Gene Bank) and calculating the amount of intracellular protein in which tyrosine is phosphorylated. Since the tyrosine phosphorylation level of intracellular protein in SR-3Y1 cells for use in this method is increased by v-Src tyrosine kinase, the ability of radicicol derivatives to inhibit v-Src tyrosine kinase can be detected as reduction of the amount of protein in which tyrosine is phosphorylated. Robinson, S.P. *et al.* [*International Journal of Oncology*, 2, 253 (1993)] report a method for examination of tyrosine phosphorylation inhibition effect by Western blotting analysis, and Kwon, H.J. *et al.* [*Cancer Research*, 52, 6926 (1992)] report examples of experiment using SR-3Y1 cells.

## DISCLOSURE OF THE INVENTION

An object of the present invention is to provide novel radicicol derivatives or pharmacologically acceptable salts thereof which show tyrosine kinase inhibition activity and have antitumor, antimicrobial or immunosuppression effects.

The present invention relates to radicicol derivatives represented by the following formula (I) or pharmacologically acceptable salts thereof:



wherein  $R^1$  and  $R^2$  are the same or different and each represents hydrogen, alkanoyl, alkenoyl or tert-butyldimethylsilyl;

15

(1)

when X represents halogen,

20

Y represents an oxygen atom or  $R^4$ -O-N


{wherein  $R^4$  represents hydrogen or substituted or unsubstituted lower alkyl

(said substituent is selected from hydroxyl, lower alkoxy, lower alkanoyloxy, azido, amino, mono- or di-lower alkylamino, lower alkanoylamino, lower alkoxycarbonylamino, lower alkenyloxycarbonylamino, carboxy, lower alkoxycarbonyl, lower alkylcarbamoyl and cyclic imido); and

$R^3$  represents hydrogen, alkanoyl, alkenoyl or -SO-Z

25

(wherein Z represents the following formula (A):



{wherein  $X^A$ ,  $R^{1A}$  and  $R^{2A}$  have the same meaning as X,  $R^1$  and  $R^2$ , respectively; and  
 $Y^A$  represents an oxygen atom or  $R^{4A}$ -O-N  
 (wherein  $R^{4A}$  has the same meaning as  $R^4$ )};

40

and  
 (2)

when X and  $R^3$  are combined with each other to represent a single bond;

45

Y represents  $R^{4B}$ -O-N

(wherein  $R^{4B}$  has the same meaning as  $R^4$ ).

Hereinafter, the compound represented by formula (I) will be called Compound (I). Compounds of other formula numbers with also be called in the same manner.

50

In the definition of each group of Compound (I), the alkanoyl means a straight or branched group having 1 to 20 carbon atoms (e.g., formyl, acetyl, propanoyl, butanoyl, caproyl, lauroyl, myristoyl, palmitoyl, stearoyl and the like). The alkenoyl means a straight or branched group having 3 to 20 carbon atoms (e.g., palmitoleoyl, linoleoyl, linolenoyl and the like). The halogen means an atom of fluorine, chlorine, bromine or iodine. The lower alkyl means a straight or branched group having 1 to 8 carbon atoms (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, octyl and the like).

55

The substituent of the substituted lower alkyl is the same or different 1 to 3 groups (e.g., hydroxyl, lower alkoxy, lower alkanoyloxy, azido, amino, mono- or di-lower alkylamino, lower alkanoylamino, lower alkoxycarbonylamino, lower

alkenyloxy-carbonylamino, carboxy, lower alkoxy-carbonyl, lower alkyl-carbamoyl, cyclic imido and the like). The lower alkyl-carbamoyl means a group substituting 1 to 2 lower alkyl on the nitrogen atom of carbamoyl.

Herein, the lower alkyl moiety of the lower alkoxy, lower alkanoyloxy, mono- or di-lower alkylamino, lower alkanoylamino, lower alkoxy-carbonylamino, lower alkoxy-carbonyl and lower alkyl-carbamoyl is the same as the lower alkyl defined above, and one of its carbon atoms may be substituted with a silicon atom. The lower alkenyl moiety of the lower alkenyloxy-carbonylamino represents a straight or branched group having 2 to 6 carbon atoms (e.g., vinyl, allyl, butenyl, pentenyl, hexenyl, pentadienyl, hexadienyl and the like). The cyclic imido represents, for example, phthalimido, succinimido, glutarimido and the like.

The pharmacologically acceptable salt of Compound (I) include an acid addition salt, a metal salt, an ammonium salt, an organic amine addition salt, an amino acid addition salt and the like. Examples of the acid addition salt include inorganic acid salts (e.g., hydrochloride, hydrobromide, sulfate, phosphate and the like), and organic acid salts (e.g., formate, acetate, oxalate, benzoate, methanesulfonate, p-toluenesulfonate, maleate, fumarate, tartrate, citrate, succinate, lactate and the like). Examples of the metal salt include alkali metal salts (e.g., lithium salt, sodium salt; potassium salt and the like), alkaline earth metal salts (e.g., magnesium salt, calcium salt and the like), aluminum salt, zinc salt and the like. Examples of the ammonium salt include salts with ammonium, tetramethylammonium and the like. Examples of the organic amine addition salt include addition salts with morpholine, piperidine and the like. Examples of the amino acid addition salt include addition salts with glycine, phenylalanine, aspartic acid, glutamic acid, lysine and the like.


The compound of the present invention is obtained generally using the optically active radicicol as the starting material, and all of possible stereoisomers and their mixtures are included in the present invention.

Next, a production method of Compound (I) is described.

The process for producing Compound (I) comprises reaction steps mainly including oxime formation (step 1), halo-hydrin formation (step 2) and acylation (step 3). These reaction steps can be combined depending on the object compound.

In the production method shown below, when a defined group changes under the employed method or is not fit for carrying out the method, the object compound can be obtained by using an introduction-elimination method of protecting groups usually used in organic synthetic chemistry [for example, see Protective Groups in Organic Synthesis, T.W. Greene, John Wiley & Sons Inc. (1981)]. Also, if necessary, the order of reaction steps such as introduction of substituents may be changed.

#### Production Method 1:



(In the above formula,  $\text{R}^{1a}$  and  $\text{R}^{2a}$  are groups in which tert-butyldimethylsilyl is removed from  $\text{R}^1$  and  $\text{R}^2$ , respectively, defined above; and  $\text{R}^4$  has the same meaning as defined above.)


#### Step 1:

Radicicol or Compound (C) which is obtained from radicicol by a known method (Japanese Published Unexamined Patent Application No. 226991/92) is used as the starting material compound.

Compound (Ia) can be obtained by allowing Compound (C) to react with Compound (II) or an acid addition salt thereof. Pyridine, chloroform, dichloromethane, ether, tetrahydrofuran, dimethylformamide, acetonitrile and the like may be used as the reaction solvent either alone or as a mixture thereof. When an acid addition salt of Compound (II) is used, the reaction is carried out in the presence of a base, for example, an amine (e.g., pyridine, triethylamine, diisopropylethylamine or the like), or an alkali metal carbonate or bicarbonate (e.g., sodium carbonate, potassium carbonate or the like), in an amount of 1 equivalent or more based on the acid addition salt of Compound (II), preferably using pyri-

dine which also serves as the solvent. Compound (II) or its acid addition salt is used in an amount of generally 1 equivalent or more, preferably 2 to 10 equivalents, based on radicalol. The reaction is carried out generally at 20 to 100°C for 1 to 80 hours.

#### 5 Production Method 2:



{In the above formula,  $R^{1a}$ ,  $R^{2a}$ , X and Y have the same meaning as defined above; and  $R^{3a}$  represents hydrogen, formyl or -SO-Z (wherein Z has the same meaning as defined above).}

#### Step 2-1:

A member of Compound (lb) in which  $R^{3a}$  is hydrogen can be obtained by allowing Compound (la) or (C) to react with an acid (e.g., hydrogen chloride, hydrogen bromide or the like) or Lewis acid (e.g., titanium tetrachloride or the like). Dioxane, tetrahydrofuran, ether, chloroform, dichloromethane, dimethylformamide, acetonitrile and the like may be used as the solvent either alone or as a mixture thereof. The acid or Lewis acid is used in an amount of 1 equivalent or more, preferably 1 to 10 equivalents, based on Compound (la) or (C). The reaction is carried out generally at -20 to 40°C for 10 minutes to 48 hours.


#### Step 2-2:

A member of Compound (lb) in which  $R^{3a}$  is formyl can be obtained by allowing Compound (la) or (C) to react with oxalyl chloride, phosphorous oxychloride or phosphorous oxybromide in dimethylformamide. Phosphorous oxychloride or phosphorous oxybromide is used in an amount of 1 equivalent or more, preferably 2 to 5 equivalents, based on Compound (la) or (C). The reaction is carried out generally at -10 to 40°C for 1 to 48 hours.

#### Step 2-3:

A dimer compound of Compound (lb) in which  $R^{3a}$  is -SO-Z (wherein Z has the same meaning as defined) can be obtained by allowing Compound (la) or (C) to react with thionyl chloride or thionyl bromide. Dimethylformamide, chloroform, dichloromethane, dimethyl sulfoxide, acetonitrile and the like may be used as the solvent either alone or as a mixture thereof. Thionyl chloride or thionyl bromide is used in an amount of 1 equivalent or more, preferably 2 to 10 equivalents, based on Compound (la) or (C). The reaction is carried out generally at -10 to 40°C for 1 to 48 hours.

## Production Method 3:




(In the above formula,  $R^{1a}$ ,  $R^{2a}$ , X and Y have the same meaning as defined above;  $R^{1b}$  and  $R^{2b}$  have the same meaning as  $R^{1a}$  and  $R^{2a}$ , respectively; and  $R^{3b}$  represents alkanoyl or alkenoyl.)

## Step 3:

Compound (1c) in which the hydroxyl group is modified with alkanoyl or alkenoyl can be obtained by allowing Compound (1b') to react with 1 equivalent or more, preferably 1 to 100 equivalents, of an acid halide, an acid anhydride or a mixed acid anhydride having the object alkanoyl or alkenoyl group in the presence of a base. Although modification of optional hydroxyl group can be effected by properly carrying out introduction and elimination of a protecting group of the hydroxyl group, it is possible to modify a plurality of hydroxyl groups at the same time. Pyridine, N,N-dimethylaniline, N,N-diethylaniline or the like is used as the base in an amount of 1 equivalent or more, preferably 1 to 200 equivalents, based on Compound (1b'). The reaction is carried out in a solvent (e.g., dimethylformamide, dimethyl sulfoxide, chloroform, dichloromethane, toluene or the like). Also, it is possible to use a base (e.g., pyridine or the like) which can also serve as the solvent. In addition, the reaction can be accelerated by adding 0.1 to 4 equivalents of N,N-dimethylaminopyridine or the like. The reaction is carried out generally at  $-20$  to  $50^{\circ}\text{C}$  for 5 minutes to 24 hours.

## Production Method 4:



{In the above formula, X, Y and  $R^3$  have the same meaning as defined above;  $R^{1c}$  and  $R^{2c}$  are both hydrogen or one of them is hydrogen and the other is alkanoyl or alkenoyl; and  $R^{1d}$  and  $R^{2d}$  are groups in which at least one of the hydrogen atoms of the above-described  $R^{1c}$  and  $R^{2c}$  is substituted with  $t\text{-BuMe}_2\text{Si}$  (wherein  $t\text{-BuMe}_2\text{Si}$  represents tert-butyldimethylsilyl).}

## Step 4:

Compound (1e) can be obtained by allowing Compound (1d) to react with tert-butyldimethylsilyl chloride in the presence of a base. Chloroform, dichloromethane, ether, tetrahydrofuran, acetone, dimethylformamide, acetonitrile and the like may be used as the solvent either alone or as a mixture thereof. Amines (e.g., pyridine, imidazole, triethylamine,

diisopropylethylamine and the like) may be used as the base. Tert-butyldimethylsilyl chloride is used in an amount of generally 1 equivalent or more, preferably 1 to 10 equivalents, based on Compound (Id). The base is used in an amount of generally 1 equivalent or more, preferably 1 to 5 equivalents, based on tert-butyldimethylsilyl chloride. The reaction is carried out generally at 0 to 50°C for 10 minutes to 24 hours.

5 In the production of Compound (I), conversion of the functional group of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X or Y can be effected not only by the aforementioned steps but also by known methods [for example, Comprehensive Organic Transformations, R.C. Larock, (1989)].

Isolation and purification of the products of the aforementioned methods can be effected by carrying out optional combinations of techniques generally used in organic syntheses (e.g., filtration, extraction, washing, drying, concentra-  
10 tion, crystallization, various types of chromatography and the like). The intermediates may be used in the subsequent reactions without purification.

If it is desirable to obtain a salt of Compound (I), the salt of Compound (I) can be purified as such when it can be obtained; or, when the compound is obtained in its free form, its salt can be formed by dissolving or suspending it in an appropriate solvent and adding an acid or base thereto.

15 Also, Compound (I) or its pharmacologically acceptable salts may exist in the form of addition products with water or various solvents, and these addition products are also included in the present invention.

Examples of Compound (I) are shown in Table 1.

20

25

30

35

40


45

50


55

Table 1 (1)

Examples of Compound (I)



Compound	R <sup>1</sup> , R <sup>2</sup>	R <sup>3</sup>	X	Y
1	H	HCO	Cl	O
2	H	H	Cl	O
3	H	H	Br	O
4	H	Z <sup>a</sup>	Cl	O
5	CH <sub>3</sub> CO	CH <sub>3</sub> CO	Cl	O
6	CH <sub>3</sub> CO	HCO	Cl	O
7	CH <sub>3</sub> CO	Z <sup>a</sup>	Cl	O
8	H	—		NOH
9	H	—		NOCH <sub>3</sub>
10	(CH <sub>3</sub> ) <sub>3</sub> C(CH <sub>3</sub> ) <sub>2</sub> Si	—		O
11	(CH <sub>3</sub> ) <sub>3</sub> C(CH <sub>3</sub> ) <sub>2</sub> Si	—		NOH
12	(CH <sub>3</sub> ) <sub>3</sub> C(CH <sub>3</sub> ) <sub>2</sub> Si	—		NOCH <sub>2</sub> OCH <sub>3</sub>
13	H	—		NOCH <sub>2</sub> OCH <sub>3</sub>
14	H	—		NO(CH <sub>2</sub> ) <sub>3</sub> N <sub>3</sub>
15	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>14</sub> CO	HCO	Cl	O
16	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>14</sub> CO	Z <sup>a</sup>	Cl	O

(wherein R<sup>1A</sup> and R<sup>2A</sup> have the same meaning as R<sup>1</sup> and R<sup>2</sup>,


respectively.)

In the definition of R<sup>3</sup> and X, "—" represents a single bond formed by combining R<sup>3</sup> and X with each other.



Table 1 (2)

## Examples of Compound (I)




Compound	R¹, R²	R³	X	Y
17	CH₃(CH₂)₁₄CO	H	Cl	O
18	CH₃(CH₂)₁₄CO	CH₃CO	Cl	O
19	CH₃(CH₂)₁₄CO	H	Br	O
20	CH₃(CH₂)₁₄CO	CH₃CO	Br	O
21	CH₃(CH₂)₁₄CO	CH₃(CH₂)₁₄CO	Br	O
22	(CH₃)₃C(CH₃)₂Si	—		NO(CH₂)₆Pht
23	H	—		NO(CH₂)₆Pht
24	H	—		NO(CH₂)₆N₃
25	H	—		NO(CH₂)₅CO₂C(CH₃)₃
26	H	—		NO(CH₂)₅CO₂(CH₂)₂Si(CH₃)₃
27	H	—		NO(CH₂)₆NHCO₂CH₂CH=CH₂
28	H	—		NO(CH₂)₅CO₂H
29	H	—		NOCH₂CO₂H

In the definition of R³ and X, "—" represents a single bond formed by combining R³ and X with each other.

In the definition of Y, "Pht" represents a phthalimido group.

Table 1 (3)

## Examples of Compound (I)



Compound	-R <sup>1</sup> , -R <sup>2</sup>	-R <sup>3</sup>	-X	=Y
30	-H	—		=NOCH <sub>2</sub> CON(CH <sub>3</sub> ) <sub>2</sub>
31	-H	—		=NO(CH <sub>2</sub> ) <sub>3</sub> OH
32	-CO(CH <sub>2</sub> ) <sub>14</sub> CH <sub>3</sub>	—		=NOCH <sub>3</sub>
33	-H	-H	-Cl	=NOCH <sub>3</sub>
34	-H	-H	-Br	=NOCH <sub>3</sub>
35	-H	-CHO	-Cl	=NOCH <sub>3</sub>
36	-H	-H	-Cl	=NOCH <sub>2</sub> CON(CH <sub>3</sub> ) <sub>2</sub>

In the definition of R<sup>3</sup> and X, "—" represents a single bond formed by combining R<sup>3</sup> and X with each other.

## BEST MODE OF CARRYING OUT THE INVENTION

Next, pharmacological activities of typical examples of Compound (I) are described by the following test examples.

## Test Example 1

## Inhibition Test of Intracellular Tyrosine Kinase:

SR-3Y1 cells were cultured at 37°C for 15 hours in an atmosphere of 5% carbon dioxide, using Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), to which each radical derivative to be tested has

been added in varied concentration. The thus cultured cells were lysed at 4°C for 20 minutes in a cooled buffer solution for lysis use (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 2 mM EDTA, 1 mM PMSF, 20 µM leupeptin, 0.15 unit/ml aprotinin, 1 mM Na<sub>3</sub>VO<sub>4</sub>) and then centrifuged at 20,000 g for 30 minutes. After measuring protein concentration in the resulting supernatant fluid, samples were adjusted to the same protein quantity per lane to carry out separation of protein by SDS-PAGE. The thus separated protein samples were transferred onto a nitrocellulose membrane to which were subsequently added a mouse polyclonal phosphotyrosine antibody MX-pTYR (Kyowa Medex Co., Ltd.) as a first antibody and a horseradish peroxidaseconjugated mouse IgG antibody (BIO-RAD Co.) as a second antibody, thereby effecting their reactions with the protein samples on the membrane. Detection was carried out using ECL reagent (Amersham Co.), and the amount of tyrosine-phosphorylated protein was determined by scanning the density of bands obtained on an X-ray film. The activity of radicicol derivatives to inhibit tyrosine phosphorylation can be shown as a concentration (IC<sub>50</sub>) of each derivative by which the ratio of tyrosine-phosphorylated protein is reduced to half in comparison with a control to which the drug is not added.

The results are shown in Table 2.

Table 2

Inhibitory Activity of Intracellular Tyrosine Kinase	
Compound	IC <sub>50</sub> (µM)
Radicicol	0.18
8	0.02
9	<0.05
10	0.15
11	0.02
14	<0.05

According to Table 2, Compound (I) shows clearly strong action to inhibit intracellular tyrosine kinase activity in comparison with radicicol and therefore is useful as a tyrosine kinase inhibitor.

#### Test Example 2

##### Cell Growth Inhibition Test on HeLa S<sub>3</sub> Cells:

HeLa S<sub>3</sub> cells which have been adjusted to 3.0×10<sup>4</sup> cells/ml with MEM medium (manufactured by Nissui Pharmaceutical) containing 10% fetal calf serum and 2 mM glutamic acid were dispensed in 0.1 ml/well portions into a 96 well microtiter plate. The cells were cultured at 37°C for 20 hours in a carbon dioxide gas incubator, the culture supernatant was removed and then the plate was washed once with physiological saline. Next, 0.1 ml of the medium containing each test compound was added to each well, and the cells were cultured at 37°C for 72 hours in the carbon dioxide gas incubator. After removing the culture supernatant, 0.1 ml of the medium containing 0.02% Neutral Red was added to each well, and the cells were stained at 37°C for 1 hour in the carbon dioxide gas incubator. After removing the culture supernatant, the plate was washed once with physiological saline, the pigment was extracted with 0.001 N hydrochloric acid/30% ethanol and then absorption at 550 nm was measured by a microplate reader. The concentration of each test compound which inhibits 50% of the cell growth (IC<sub>50</sub>) was calculated by comparing the absorption of untreated cells with that of the cells treated with known concentration of each sample.

The results are shown in Table 3.

Table 3

Cell Growth Inhibition Activity upon HeLa S <sub>3</sub> Cells	
Compound	IC <sub>50</sub> (μM)
Radicicol	6.7
4	6.0
6	5.0
7	1.5
8	0.09
9	0.05
10	3.2
11	0.12
13	0.02
14	0.05

According to Table 3, Compound (I) shows a cell growth inhibition activity upon HeLa S<sub>3</sub> cells, which is stronger than that of the known radicicol and therefore is useful as an antitumor agent.

#### Test Example 3

##### Antitumor Test on P388 Leukemia:

The ascitic fluid was collected from the abdominal cavity of P388 ascites-induced mouse (DBA/2) 7 days after the transplantation. The number of P388 cells in the ascitic fluid was counted to prepare a tumor cell suspension of  $5 \times 10^6$  cells/ml using sterilized physiological saline, and its 0.2 ml portion (containing  $1 \times 10^6$  cells) was transplanted into the abdominal cavity of CDF<sub>1</sub> mice having 20 to 25 g in body weight. Each of the test compounds was dissolved in physiological saline containing polyoxyethylene sorbitan monolaurate, its 0.2 ml portion was administered into the abdominal cavity of CDF<sub>1</sub> mice of 5 animals per group 24 hours after the tumor transplantation and then their survival days were observed for 30 days. Effects of the test compounds were judged by the ratio of average survival days in the test compound-administered group to that in the control group (un-treated group) (increased life span, ILS%).

The results are shown in Table 4.

Table 4

Antitumor Activity upon P388 Leukemia	
Compound	ILS (%)
Radicicol	27
1	38
3	46
4	42

According to Table 4, Compound (I) shows excellent increased life span in comparison with radicicol and therefore is useful as an antitumor agent.

## Test Example 4

## Antitumor Test on Sarcoma 180 Solid Tumor:

5 Seven days after transplantation of  $5 \times 10^6$  of sarcoma 180 cells into the abdominal cavity of a ddY mouse, the cells were collected from the ascitic fluid, washed once with sterilized physiological saline and then made into a cell suspension of  $5 \times 10^7$  cells/ml using sterilized physiological saline. A 0.1 ml portion of the cell suspension was transplanted under the skin of the right side axillary part of ddY mice of  $20 \pm 2$  g in body weight and, after 24 hours of the tumor transplantation, 0.1 to 0.2 ml of each test compound dissolved in physiological saline or polyoxyethylene sorbitan monolau-  
10 rate-containing physiological saline was administered by intravenous injection to ddY mice of 5 animals per group. The major axis (a) and the minor axis (b) of each tumor 7 days after the transplantation were measured to calculate the tumor volume as an  $a \times b^2/2$  value. Antitumor activity of each test compound was expressed by the ratio (T/C) of the tumor volume (T) of the test compound-administered group to the tumor volume (C) of the control group in which the drug was not administered.

15 The results are shown in Table 5.

Table 5

Antitumor Activity upon Sarcoma 180 Solid Tumor	
Compound	T/C (%)
Radicicol	88
1	51
2	50
4	39

20  
25  
30 According to Table 5, Compound (I) shows excellent antitumor activity in comparison with radicol and therefore is useful as an antitumor agent.

## Test Example 5

## 35 Antibacterial Activity Test:

The antibacterial activity was measured by an agar dilution method using a medium (pH 7) which has been prepared by dissolving 3 g of Bacto-Tryptone (manufactured by Difco), 3 g of meat extract, 1 g of yeast extract, 1 g of glucose and 16 g of agar in 1 l of water. The antibacterial activity was expressed by minimum growth inhibition  
40 concentration (MIC).

The results are shown in Table 6.

Table 6

Antibacterial Activity			
Compound	Minimum Growth Inhibition Concentration ( $\mu\text{g/ml}$ )		
	CA	BS	EH
Radicicol	20	83	-
1	-	83	-
3	-	83	-
4	2.6	1.3	2.6
9	6.5	52	-
CA: <i>Candida albicans</i> ATCC 10231 BS: <i>Bacillus subtilis</i> No. 10707 EH: <i>Enterococcus hirae</i> ATCC 10541			

According to Table 6, Compound (I) shows antibacterial activity and therefore is useful as an antibacterial agent.

#### Test Example 6

#### T Cell Growth Inhibition Test by Mixed Mouse Lymphocyte Culture Reaction:

The spleen was excised aseptically from an AKR mouse (Japan SLC Co., Ltd.) and made into a single cell suspension. The suspension was mixed with mitomycin C (MMC) (Kyowa Hakko Kogyo Co., Ltd.) (final concentration, 50  $\mu\text{g/ml}$ ) and cultured at 37°C for 30 minutes. After the culturing, the cells were washed three times with a solution (HBSS) prepared by adding 2.5% fetal calf serum (FCS, Gibco Co.) to Hanks' balanced salt solution (Gibco Co.) and then adjusted to a density of  $1 \times 10^7$  cells/ml.

A 50  $\mu\text{l}$  portion of B10.BR mouse (Japan SLC Co., Ltd.) lymph node cell suspension (containing  $1.5 \times 10^5$  cells), 50  $\mu\text{l}$  of AKR mouse spleen cell suspension (containing  $5 \times 10^5$  cells) and 100  $\mu\text{l}$  of radicicol solution having each test concentration were added to each well of a 96 well microtiter plate and cultured at 37°C for 72 hours in a CO<sub>2</sub> incubator. A 1.0  $\mu\text{Ci}$  portion of [<sup>3</sup>H]-thymidine was added 18 hours before the completion of the culturing. After completion of the culturing, the cells were trapped on a filter paper using a cell harvester and dried, and then a toluene scintillator was added thereto to measure the amount of radioactivity of [<sup>3</sup>H]-thymidine incorporated into cells using a scintillation counter (test group). As a control group, the same culturing was carried out without adding the solution of Compound (I) and then the amount of radioactivity of [<sup>3</sup>H]-thymidine incorporated into cells was measured. The T cell growth inhibition ratio was calculated based on the following formula, from which the concentration of each test compound that inhibits 50% of the growth (IC<sub>50</sub>) was calculated.

$$\text{T Cell Growth Inhibition Ratio (\%)} = \frac{\text{Radioactivity in Control Group} - \text{Radioactivity in Test Group}}{\text{Radioactivity in Control Group} - [\text{Radioactivity in MMC-Treated AKR Mouse} + \text{Radioactivity in B10.BR Mouse Before Stimulation}]}$$

(In the above formula, the radioactivity in MMC-treated AKR mouse means the radiation dose of [<sup>3</sup>H]-thymidine incorporated into MMC-treated AKR mouse spleen cells, and the radioactivity in B10.BR mouse means the radiation dose of [<sup>3</sup>H]-thymidine incorporated into B10.BR mouse lymph node cells.)

The results are shown in Table 7.

Table 7

T Cell Growth Inhibition Ratio (%) by Mixed Mouse Lymphocyte Culture Reaction	
Compound	IC <sub>50</sub> (μM)
Radicicol	0.15
3	0.3
8	0.01
9	0.02
19	0.15

According to Table 7, Compound (I) inhibited growth of T cells by the mixed mouse lymphocyte culture reaction, thus showing clear immunosuppression action. In addition, the suppression action was superior to that in the prior art of radicicol.

Compound (I) or a pharmacologically acceptable salt thereof is applied by oral or parenteral administration as it is or in the form of a pharmaceutical composition. Examples of the dosage form of such a pharmaceutical composition include tablets, pills, powders, granules, capsules, suppositories, injections, drip infusions and the like.

These dosage forms can be prepared by employing generally known methods and may contain various fillers, lubricants, binders, disintegrators, suspending agents, tonicity agents, emulsifying agents, absorption enhancers and the like.

Examples of carriers to be used in the pharmaceutical composition include water, distilled water for injection use, physiological saline, glucose, fructose, sucrose, mannitol, lactose, starch, corn starch, cellulose, methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, alginic acid, talc, sodium citrate, calcium carbonate, calcium hydrogenphosphate, magnesium stearate, urea, silicone resin, sorbitan fatty acid ester, glycerol fatty acid ester and the like, which may be optionally selected in response to the type of the pharmaceutical preparation.

Although the dosage and the number of administration times for the aforementioned purposes may vary depending on the intended therapeutic effect, administration method, treating period, age, body weight and the like, it may be administered generally in a dose of 0.01 to 5 mg/kg per day per adult.

The mode of the present invention will be described with reference to the following examples and reference examples. In this connection, structural formula of each compound is shown in Table 1 above.

#### Example 1

##### Compound 1:

A 1 ml portion of phosphorus oxychloride was added dropwise to 5 ml of dimethylformamide which was cooled in an ice bath. After 30 minutes of stirring at room temperature, the thus prepared solution was slowly added to a dimethylformamide solution (20 ml) of radicicol (2 g) while stirring in an ice bath, and the mixture was then stirred at room temperature for 24 hours. The reaction solution was diluted with ethyl acetate (200 ml), washed three times with water and then dried with anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 1.4 g of Compound 1.

<sup>1</sup>HMR(CD<sub>3</sub>OD) δ (ppm): 8.00 (1H, s), 7.14 (1H, ddd, 1.0, 11.2, 16.1 Hz), 6.44 (1H, s), 6.16 (1H, t, 10.8 Hz), 5.95 (1H, d, 16.1 Hz), 5.68 (1H, t, 10.0 Hz), 5.32 (1H, m), 5.25 (1H, m), 5.20 (1H, dd, 5.6, 10.0 Hz), 4.10 (1H, d, 16.1 Hz), 3.65 (1H, d, 16.1 Hz), 1.97 (1H, m), 1.42 (3H, d, 6.3 Hz)  
FAB-MS m/z: 429 [M+H]<sup>+</sup>

#### Example 2

##### Compound 2:

A 1.3 ml portion of concentrated hydrochloric acid (36%) was added dropwise to a dioxane solution (70 ml) of

radicol (2 g) while cooling in an ice bath, and the mixture was stirred at room temperature for 6 hours. The reaction solution was mixed with water (100 ml), carefully neutralized with saturated sodium bicarbonate aqueous solution while cooling in an ice bath and then extracted three times with ethyl acetate (150 ml). The extract was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 1 g of Compound 2.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.25 (1H, ddd, 1.0, 11.3, 16.4 Hz), 6.50 (1H, s), 6.21 (1H, dt, 1.0, 11.7 Hz), 5.99 (1H, d, 16.4 Hz), 5.79 (1H, dt, 1.0, 11.7 Hz), 5.42 (1H, m), 5.17 (1H, ddd, 1.0, 5.9, 11.7 Hz), 4.25 (1H, d, 16.4 Hz), 4.03 (1H, dd, 5.9, 8.1 Hz), 3.70 (1H, d, 16.4 Hz), 2.07 (1H, ddd, 1.2, 6.8, 15.1 Hz), 1.93 (1H, ddd, 3.7, 8.1, 15.1 Hz), 1.46 (3H, d, 6.3 Hz)  
FAB-MS m/z: 401 [M+H]<sup>+</sup>

### Example 3

#### Compound 3:

A 1.0 ml portion of concentrated hydrobromic acid (47%) was added dropwise to a dioxane solution (50 ml) of radicol (2.5 g) while cooling in an ice bath, and the mixture was stirred at room temperature for 2 hours. The reaction solution was mixed with water (100 ml), carefully neutralized with saturated sodium bicarbonate aqueous solution while cooling in an ice bath and then extracted three times with ethyl acetate (150 ml). The extract was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 1.7 g of Compound 3.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.28 (1H, dd, 10.8, 16.0 Hz), 6.51 (1H, s), 6.13 (1H, t, 10.8 Hz), 6.00 (1H, d, 16.0 Hz), 5.96 (1H, t, 10.8 Hz), 5.40 (1H, m), 5.33 (1H, dd, 5.2, 10.8 Hz), 4.24 (1H, d, 16.1 Hz), 4.18 (1H, m), 3.71 (1H, d, 16.1 Hz), 2.08 (1H, m), 1.92 (1H, m), 1.45 (3H, d, 6.4 Hz)  
FAB-MS m/z: 445, 447 [M+H]<sup>+</sup>

### Example 4

#### Compound 4:

A 0.5 ml portion of thionyl chloride was added dropwise to a dimethylformamide solution (7.5 ml) of radicol (1.4 g) while cooling in an ice bath, and the mixture was stirred at room temperature for 12 hours. The reaction solution was diluted by adding ethyl acetate (100 ml) and washed three times with water. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (4% methanol/chloroform) to obtain 1.0 g of Compound 4.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.15 (2H, dd, 10.8, 16.1 Hz), 6.52 (2H, s), 6.27 (2H, t, 10.8 Hz), 6.05 (2H, d, 16.1 Hz), 5.73 (2H, t, 10.8 Hz), 5.39 (2H, m), 5.35 (2H, m), 4.88 (2H, m), 4.28 (2H, d, 16.4 Hz), 3.74 (2H, d, 16.4 Hz), 2.27 (2H, m), 2.10 (2H, m), 1.50 (6H, d, 6.3 Hz)  
FAB-MS m/z: 847 [M+H]<sup>+</sup>

### Example 5

#### Compound 5:

A 0.75 ml portion of acetic anhydride was added to an anhydrous pyridine solution (1 ml) of Compound 2 (170 mg), and the mixture was stirred at room temperature for 10 hours. The reaction solution was diluted with 20 ml of ethyl acetate and then washed with water, dilute hydrochloric acid aqueous solution and saturated sodium bicarbonate aqueous solution in that order. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2:1 n-hexane/ethyl acetate) to obtain 125 mg of Compound 5.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.06 (1H, s), 6.93 (1H, dd, 11.2, 16.3 Hz), 6.12 (1H, t, 11.2 Hz), 6.04 (1H, d, 16.1 Hz), 5.73 (1H, t, 11.2 Hz), 5.40 (1H, m), 5.14 (1H, t, 8.0 Hz), 5.00 (1H, ddd, 1.1, 8.0, 11.2 Hz), 4.41 (1H, d, 16.3 Hz), 3.96 (1H, d, 16.3 Hz), 2.35 (3H, s), 2.34 (3H, s), 2.21 (1H, dd, 8.7, 15.4 Hz), 2.04 (1H, ddd, 3.3, 8.7, 15.4 Hz), 1.96 (3H, s), 1.54 (3H, d, 6.3 Hz)



FAB-MS m/z: 527 [M+H]<sup>+</sup>

## Example 6

## 5 Compound 6:

Acetic anhydride (1 ml) was added to a pyridine solution (1 ml) of Compound 1 (166 mg), and the mixture was stirred at room temperature for 13 hours. The reaction solution was diluted with water and then extracted with ethyl acetate (50 ml × 3). The extract was washed with dilute hydrochloric acid aqueous solution, saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution in that order. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2:1 n-hexane/ethyl acetate) to obtain 174 mg of Compound 6.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.99 (1H, s), 7.07 (1H, s), 6.93 (1H, dd, 11.1, 16.3 Hz), 6.14 (1H, t, 11.1 Hz), 6.04 (1H, d, 16.3 Hz), 5.75 (1H, t, 11.1 Hz), 5.43 (1H, m), 5.34 (1H, t, 7.5 Hz), 5.05 (1H, dd, 7.5, 11.1 Hz), 4.31 (1H, d, 16.2 Hz), 3.96 (1H, d, 16.2 Hz), 2.35 (3H, s), 2.34 (3H, s), 2.14 (1H, m), 2.06 (1H, m), 1.57 (3H, d, 6.4 Hz)  
FAB-MS m/z: 513 [M+H]<sup>+</sup>

## Example 7

## 20 Compound 7:

Acetic anhydride (0.5 ml) was added to a pyridine solution (0.5 ml) of Compound 4 (30 mg), and the mixture was stirred at room temperature for 13 hours. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (1:1 n-hexane/ethyl acetate) to obtain 30 mg of Compound 7.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.06 (2H, s), 6.88 (2H, dd, 11.0, 15.9 Hz), 6.17 (2H, t, 10.8 Hz), 6.05 (2H, d, 16.3 Hz), 5.67 (2H, t, 10.4 Hz), 5.45 (2H, m), 5.05 (2H, dd, 7.8, 9.7 Hz), 4.82 (2H, dd, 8.5, 8.4 Hz), 4.30 (2H, d, 15.8 Hz), 3.95 (2H, d, 15.8 Hz), 2.338 (6H, s), 2.337 (6H, s), 2.25 (2H, m), 2.06 (2H, m), 1.54 (6H, d, 6.4 Hz)  
FAB-MS m/z: 1015 [M+H]<sup>+</sup>

## Example 8

## 35 Compound 8:

Hydroxylamine hydrochloride (20 mg) was added to a pyridine solution (2 ml) of radicicol (42 mg), and the mixture was stirred at 50°C for 8 hours. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (25:1 chloroform/methanol) to obtain 10 mg of Compound 8. Compound 8 thus obtained was identified by <sup>1</sup>H-NMR to find that it was a mixture (about 3:1) of isomers due to the oxime hydroxyl group.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.22 (1H, dd, 11.3, 16.2 Hz), 7.12 (0.5H, dd, 11.2, 16.1 Hz), 6.83 (1.5H, d, 16.2 Hz), 6.43 (1H, s), 6.42 (0.5H, s), 6.16 (1H, t, 11.3 Hz), 6.11 (0.5H, t, 11.2 Hz), 5.58 (1H, dd, 3.6, 11.3 Hz), 5.46 (0.5H, dd, 3.4, 11.2 Hz), 5.30 (1.5H, m), 4.79 (0.5H, d, 16.3 Hz), 4.72 (0.5H, d, 16.3 Hz), 3.91 (1H, d, 16.1 Hz), 3.81 (1H, d, 16.1 Hz), 3.35 (1.5H, m), 3.02 (1.5H, m), 2.97 (0.5H, m), 2.42 (1.5H, m), 1.60 (1.5H, m), 1.53 (3H, d, 6.6 Hz), 1.52 (1.5H, d, 7.7 Hz)  
FAB-MS m/z: 380 [M+H]<sup>+</sup>

## Example 9

## 50 Compound 9:

O-Methylhydroxylamine hydrochloride (100 mg) was added to a pyridine solution (1 ml) of radicicol (200 mg), and the mixture was stirred at 80°C for 90 minutes. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 34 mg of Compound 9.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.23 (1H, dd, 11.3, 16.2 Hz), 6.70 (1H, d, 16.2 Hz), 6.42 (1H, s), 6.14 (1H, t, 11.3 Hz), 5.58 (1H, dd, 3.6, 11.3 Hz), 5.30 (1H, m), 3.904 (1H, d, 16.1 Hz), 3.901 (3H, s), 3.80 (1H, d, 16.1 Hz), 3.33 (1H, m),

3.01 (1H, m), 2.42 (1H, ddd, 3.5, 3.5, 14.5 Hz), 1.59 (1H, ddd, 4.1, 9.0, 14.5 Hz), 1.52 (3H, d, 6.5 Hz)

FAB-MS  $m/z$ : 394  $[M+H]^+$

#### Example 10

##### Compound 10:

A dimethylformamide solution (7.5 ml) of radicicol (500 mg) was cooled in an ice bath and mixed with dimethylformamide solutions (2.5 ml) of imidazole (700 mg) and t-butyldimethylsilane chloride (1.1 g) in that order, and the mixture was stirred at room temperature for 12 hours. The reaction solution was diluted by adding ethyl acetate (50 ml) and then washed twice with water. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (3:1 n-hexane/ethyl acetate) to obtain 902 mg of Compound 10.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.58 (1H, dd, 10.8, 16.2 Hz), 6.39 (1H, s), 6.13 (1H, ddd, 1.1, 10.8, 10.8 Hz), 6.04 (1H, d, 16.2 Hz), 5.78 (1H, dd, 3.5, 10.8 Hz), 5.32 (1H, m), 3.89 (1H, d, 16.3 Hz), 3.70 (1H, d, 16.3 Hz), 3.40 (1H, ddd, 1.9, 1.9, 3.4 Hz), 3.02 (1H, ddd, 1.9, 2.3, 9.4 Hz), 2.44 (1H, ddd, 3.2, 3.2, 14.4 Hz), 1.54 (3H, d, 6.6 Hz), 1.50 (1H, m), 1.00 (9H, s), 0.94 (9H, s), 0.24 (3H, s), 0.22 (3H, s), 0.21 (3H, m), 0.20 (3H, s)

FAB-MS  $m/z$ : 593  $[M+H]^+$

#### Example 11

##### Compound 11:

Pyridine (0.1 ml) and hydroxylamine hydrochloride (240 mg) were added to a dichloromethane solution (5 ml) of Compound 10 (319 mg), and the mixture was stirred at 70°C for 30 hours. The reaction solution was cooled to room temperature, diluted with chloroform and then washed with dilute hydrochloric acid aqueous solution, saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution in that order. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (1:1 n-hexane/ethyl acetate) to obtain 18 mg of Compound 11. Compound 11 thus obtained was identified by  $^1\text{H-NMR}$  to find that it was a mixture (about 1:1) of isomers due to the oxime hydroxyl group.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.24 (1H, dd, 11.3, 16.1 Hz), 7.13 (1H, dd, 11.2, 16.0 Hz), 6.87 (1H, d, 16.1 Hz), 6.37 (1H, s), 6.36 (1H, s), 6.20 (1H, d, 16.0 Hz), 6.14 (1H, t, 11.3 Hz), 6.08 (1H, t, 11.2 Hz), 5.65 (1H, dd, 3.0, 11.3 Hz), 5.53 (1H, dd, 3.1, 11.2 Hz), 5.26 (2H, m), 4.85 (1H, d, 16.3 Hz), 3.91 (1H, d, 16.2 Hz), 3.60 (1H, d, 16.2 Hz), 3.39 (2H, m), 3.01 (1H, d, 16.3 Hz), 2.98 (2H, m), 2.42 (2H, m), 1.56 (3H, d, 6.5 Hz), 1.54 (3H, d, 6.5 Hz), 1.49 (2H, m), 1.00 (18H, s), 0.943 (9H, s), 0.942 (9H, s), 0.23 (6H, s), 0.212 (6H, s), 0.209 (6H, s), 0.20 (6H, s)

FAB-MS  $m/z$ : 608  $[M+H]^+$

#### Example 12

##### Compound 12:

Diisopropylethylamine (160  $\mu\text{l}$ ) and chloromethyl methyl ether (75  $\mu\text{l}$ ) were added in that order at 0°C to a dichloromethane solution (1 ml) of Compound 11 (100 mg), and the mixture was stirred at 0°C for 7 hours. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (5:1 n-hexane/ethyl acetate) to obtain 58 mg of Compound 12. Compound 12 thus obtained was identified by  $^1\text{H-NMR}$  to find that it was a mixture (about 1:1) of isomers due to the oxime hydroxyl group.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.24 (1H, dd, 11.2, 16.1 Hz), 7.12 (1H, dd, 11.2, 16.1 Hz), 6.81 (1H, d, 16.1 Hz), 6.36 (2H, s), 6.12 (1H, ddd, 2.0, 11.2, 11.2 Hz), 6.07 (1H, ddd, 1.5, 11.2, 11.2 Hz), 5.66 (1H, dd, 2.9, 11.2 Hz), 5.52 (1H, dd, 3.2, 11.2 Hz), 5.28 (2H, m), 5.22 (2H, ABq, 7.3 Hz), 5.18 (2H, s), 4.81 (1H, d, 16.4 Hz), 3.97 (1H, d, 16.4 Hz), 3.59 (1H, d, 16.4 Hz), 3.50 (3H, s), 3.48 (3H, s), 3.37 (2H, m), 3.05 (1H, d, 16.4 Hz), 3.02-2.94 (2H, m), 2.45-2.39 (2H, m), 1.56 (3H, d, 7.8 Hz), 1.54 (3H, d, 6.6 Hz), 1.00 (18H, s), 0.943 (9H, s), 0.940 (9H, s), 0.23 (6H, s), 0.21 (6H, s), 0.204 (6H, s), 0.200 (6H, s)

FAB-MS  $m/z$ : 652  $[M+H]^+$

## Example 13

## Compound 13:

A 1 M tetrahydrofuran solution (50  $\mu$ l) of tetra-n-butylammonium fluoride was added to a tetrahydrofuran solution (0.5 ml) of Compound 12 (22 mg), and the mixture was stirred at room temperature for 2 hours. The reaction solution was diluted with ethyl acetate and then washed twice with water. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 11 mg of Compound 13. Compound 13 thus obtained was identified by  $^1\text{H-NMR}$  to find that it was a mixture (about 1:1) of isomers due to the oxime hydroxyl group.

$^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  (ppm): 7.29 (1H, dd, 11.2, 16.1 Hz), 7.18 (1H, dd, 11.0, 16.1 Hz), 6.77 (1H, d, 16.1 Hz), 6.43 (2H, s), 6.17 (1H, t, 11.2 Hz), 6.16 (1H, d, 16.1 Hz), 6.13 (1H, t, 11.0 Hz), 5.61 (1H, dd, 3.4, 11.2 Hz), 5.50 (1H, dd, 3.4, 11.0 Hz), 5.30 (2H, m), 5.19 (2H, ABq, 7.3 Hz), 5.13 (2H, ABq, 7.1 Hz), 4.65 (1H, d, 16.6 Hz), 3.95 (1H, d, 16.4 Hz), 3.84 (1H, d, 16.4 Hz), 3.46 (1H, d, 16.6 Hz), 3.47 (3H, s), 3.43 (3H, s), 3.33 (1H, m), 3.30 (1H, m), 3.02 (1H, m), 2.97 (1H, m), 2.42 (2H, m), 1.68-1.58 (2H, m), 1.53 (3H, d, 7.8 Hz), 1.51 (3H, d, 6.6 Hz)  
FAB-MS  $m/z$ : 424  $[\text{M}+\text{H}]^+$

## Example 14

## Compound 14:

A pyridine solution (0.5 ml) of radicicol (36.4 mg) and O-(3-azidopropyl)hydroxylamine hydrochloride (20 mg) was stirred at room temperature for 14 hours. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 29.3 mg of Compound 14.

$^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  (ppm): 7.24 (1H, ddd, 1.0, 11.2, 16.1 Hz), 6.72 (1H, d, 16.1 Hz), 6.43 (1H, s), 6.15 (1H, ddd, 1.7, 11.2, 11.2 Hz), 5.59 (1H, dd, 3.7, 11.2 Hz), 5.30 (1H, m), 4.20 (2H, m), 3.92 (1H, d, 16.1 Hz), 3.81 (1H, d, 16.1 Hz), 3.42 (2H, t, 6.6 Hz), 3.34 (1H, m), 3.01 (1H, m), 2.42 (1H, ddd, 3.4, 3.4, 14.4 Hz), 1.96 (2H, m), 1.59 (1H, ddd, 3.9, 8.8, 14.4 Hz), 1.52 (3H, d, 6.4 Hz)  
FAB-MS  $m/z$ : 463  $[\text{M}+\text{H}]^+$

## Example 15

## Compound 15:

A methylene chloride solution (2 ml) of Compound 1 (60 mg) and 4-dimethylaminopyridine (40 mg) was cooled to 0°C, palmitoyl chloride (0.1 ml) was slowly added dropwise thereto and the resulting mixture was stirred at 0°C for 30 minutes. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (4:1 n-hexane/ethyl acetate) to obtain 92 mg of Compound 15.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.98 (1H, s), 7.03 (1H, s), 6.94 (1H, dd, 11.2, 16.3 Hz), 6.14 (1H, t, 11.2 Hz), 6.04 (1H, d, 16.3 Hz), 5.74 (1H, t, 11.2 Hz), 5.40 (1H, m), 5.32 (1H, br t, 7.6 Hz), 5.05 (1H, dd, 7.6, 11.2 Hz), 4.29 (1H, d, 16.3 Hz), 3.95 (1H, d, 16.3 Hz), 2.63-2.52 (4H, m), 2.14 (1H, dd, 7.6, 15.4 Hz), 2.05 (1H, m), 1.80-1.72 (4H, m), 1.55 (3H, d, 6.3 Hz), 1.43-1.26 (48H, m), 0.88 (6H, t, 6.7 Hz)  
FAB-MS  $m/z$ : 905  $[\text{M}+\text{H}]^+$

## Example 16

## Compound 16:

A methylene chloride solution (6 ml) of Compound 4 (96 mg) and 4-dimethylaminopyridine (126 mg) was cooled to 0°C, palmitoyl chloride was slowly added dropwise thereto and the resulting mixture was stirred at 0°C for 2 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (4:1 n-hexane/ethyl acetate) to obtain 130 mg of Compound 16.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.02 (2H, s), 6.88 (2H, m), 6.16 (1H, t, 10.8 Hz), 6.15 (1H, t, 10.8 Hz), 6.04 (1H, d, 16.2 Hz), 6.03 (1H, d, 16.2 Hz), 5.66 (1H, t, 10.8 Hz), 5.64 (1H, t, 10.8 Hz), 5.43 (2H, m), 5.06 (1H, dd, 6.0, 10.8 Hz),

5.02 (1H, dd, 6.8, 9.0 Hz), 4.80 (1H, br t, 8.8 Hz), 4.68 (1H, br t, 8.6 Hz), 4.29 (1H, d, 16.3 Hz), 4.27 (1H, d, 16.2 Hz), 3.95 (2H, d, 16.3 Hz), 2.60-2.52 (8H, m), 2.29-2.18 (2H, m), 2.06 (2H, m), 1.81-1.71 (8H, m), 1.522 (3H, d, 6.3 Hz), 1.517 (3H, d, 6.3 Hz), 1.43-1.21 (96H, m), 0.88 (12H, t, 6.8 Hz)

FAB-MS  $m/z$ : 1801.9  $[M+H]^+$

#### Example 17

##### Compound 17:

Concentrated hydrochloric acid (36%, 0.5 ml) was added dropwise to a dioxane solution (5 ml) of Compound a (343 mg) obtained in Reference Example 1, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was washed with water and dried with anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (4:1 n-hexane/ethyl acetate) to obtain 96 mg of Compound 17.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.01 (1H, s), 6.95 (1H, dd, 11.1, 16.3 Hz), 6.21 (1H, t, 11.1 Hz), 6.03 (1H, d, 16.3 Hz), 5.77 (1H, t, 11.1 Hz), 5.51 (1H, m), 4.97 (1H, ddd, 1.0, 6.6, 11.1 Hz), 4.32 (1H, d, 16.2 Hz), 3.97 (1H, t, 6.6 Hz), 3.93 (1H, d, 16.2 Hz), 2.62-2.45 (4H, m), 2.12 (1H, m), 2.01 (1H, m), 1.79-1.69 (4H, m), 1.50 (3H, d, 6.3 Hz), 1.44-1.21 (48H, m), 0.88 (6H, t, 6.6 Hz)

FAB-MS  $m/z$ : 877  $[M+H]^+$

#### Example 18

##### Compound 18:

A methylene chloride solution (4 ml) of Compound 17 (25 mg) was cooled to 0°C, pyridine (5 drops) and acetyl chloride (5 drops) were added dropwise thereto and the resulting mixture was stirred at 0°C for 30 minutes. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel column chromatography (5:1 n-hexane/ethyl acetate) to obtain 15 mg of Compound 18.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.02 (1H, s), 6.93 (1H, dd, 11.2, 16.4 Hz), 6.12 (1H, t, 11.2 Hz), 6.03 (1H, d, 16.4 Hz), 5.73 (1H, t, 11.2 Hz), 5.38 (1H, m), 5.13 (1H, t, 8.0 Hz), 5.01 (1H, dd, 8.0, 11.2 Hz), 4.34 (1H, d, 16.4 Hz), 3.96 (1H, d, 16.4 Hz), 2.61-2.55 (4H, m), 2.20 (1H, m), 2.03 (1H, m), 1.95 (3H, s), 1.80-1.71 (4H, m), 1.53 (3H, d, 6.4 Hz), 1.43-1.26 (48H, m), 0.88 (6H, t, 6.6 Hz)

FAB-MS  $m/z$ : 919  $[M+H]^+$

#### Example 19

##### Compound 19:

Concentrated hydrobromic acid (47%, 3 drops) was slowly added dropwise to a dioxane solution (5 ml) of Compound a (106 mg), see below, obtained in reference Example 1, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was diluted with chloroform and washed with water. This was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (3:1 n-hexane/ethyl acetate) to obtain 41 mg of Compound 19.

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm): 7.03 (1H, s), 6.99 (1H, dd, 10.8, 16.1 Hz), 6.14 (1H, t, 10.8 Hz), 6.05 (1H, d, 16.1 Hz), 5.94 (1H, t, 10.8 Hz), 5.50 (1H, m), 5.10 (1H, dd, 5.9, 10.8 Hz), 4.29 (1H, d, 16.1 Hz), 4.13 (1H, br t, 5.9 Hz), 3.94 (1H, d, 16.1 Hz), 2.60-2.54 (4H, m), 2.13 (1H, dd, 6.9, 15.2 Hz), 2.00 (1H, m), 1.80-1.69 (4H, m), 1.50 (3H, d, 6.3 Hz), 1.44-1.26 (48H, m), 0.88 (6H, t, 6.6 Hz)

FAB-MS  $m/z$ : 921, 923  $[M+H]^+$

#### Example 20

##### Compound 20:

Pyridine (5 drops) and acetic anhydride (3 drops) were added dropwise in that order to a methylene chloride solution (1 ml) of Compound 19, and the mixture was stirred at room temperature for 16 hours. The solvent was evaporated

under reduced pressure and the resulting residue was purified by silica gel preparative thin layer chromatography (0.25 mm x 10 cm x 20 cm, 5:1 n-hexane/ethyl acetate) to obtain 4.3 mg of Compound 20.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.04 (1H, s), 6.97 (1H, dd, 10.7, 16.1 Hz), 6.05 (1H, t, 10.7 Hz), 6.04 (1H, d, 16.1 Hz), 5.89 (1H, t, 10.7 Hz), 5.38 (1H, m), 5.27 (1H, br t, 7.8 Hz), 5.09 (1H, dd, 7.8, 10.7 Hz), 4.32 (1H, d, 16.4 Hz), 3.96 (1H, d, 16.4 Hz), 2.63-2.56 (4H, m), 2.21 (1H, dd, 7.8, 14.4 Hz), 2.02 (1H, m), 1.976 (3H, s), 1.81-1.71 (4H, m), 1.53 (3H, d, 6.4 Hz), 1.47-1.23 (48H, m), 0.88 (6H, t, 6.8 Hz).  
FAB-MS m/z: 963, 965 [M+H]<sup>+</sup>

#### Example 21

Compound 21:

4-Dimethylaminopyridine (300 mg) and palmitoyl chloride (1.0 ml) were added in that order to a methylene chloride solution (10 ml) of Compound 3 (250 mg), and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (3:1 n-hexane/ethyl acetate) to obtain 130 mg of Compound 21.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.04 (1H, s), 6.97 (1H, dd, 11.0, 16.8 Hz), 6.04 (1H, t, 11.0 Hz), 6.00 (1H, d, 16.8 Hz), 5.89 (1H, t, 11.0 Hz), 5.38 (1H, m), 5.28 (1H, t, 7.6 Hz), 5.10 (1H, dd, 7.6, 11.0 Hz), 4.31 (1H, d, 16.1 Hz), 3.95 (1H, d, 16.1 Hz), 2.61-2.53 (6H, m), 2.22 (1H, dd, 7.8, 14.4 Hz), 2.01 (1H, m), 1.81-1.71 (6H, m), 1.53 (3H, d, 6.4 Hz), 1.43-1.26 (72H, m), 0.88 (6H, t, 6.8 Hz).  
FAB-MS m/z: 1160, 1162 [M+H]<sup>+</sup>

#### Example 22

Compound 22:

Diethyl azodicarboxylate (0.1 ml) was added dropwise to a tetrahydrofuran solution (1.5 ml) of Compound 11 (250 mg), N-(6-hydroxyhexyl)phthalimide (244 mg) and triphenylphosphine (135 mg), and the mixture was stirred at room temperature for 21 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (7.5:1 n-hexane/ethyl acetate) to obtain 49 mg of Compound 22.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.83 (2H, m), 7.71 (2H, m), 7.08 (1H, dd, 11.2, 16.1 Hz), 6.30 (1H, s), 6.27 (1H, d, 16.1 Hz), 6.18 (1H, dd, 10.5, 11.2 Hz), 5.48 (1H, dd, 3.2, 10.5 Hz), 5.24 (1H, m), 3.98 (1H, d, 16.1 Hz), 3.91 (2H, m), 3.69 (2H, m), 3.56 (1H, d, 16.1 Hz), 3.41 (1H, m), 2.96 (1H, m), 2.42 (1H, m), 1.83-1.37 (9H, m), 1.55 (3H, d, 6.5 Hz), 0.975 (9H, s), 0.973 (9H, s), 0.24 (3H, s), 0.22 (3H, s), 0.204 (3H, s), 0.197 (3H, s).  
FAB-MS m/z: 837 [M+H]<sup>+</sup>

#### Example 23

Compound 23:

Tetra-n-butylammonium fluoride (1 M/tetrahydrofuran solution, 0.05 ml) was added dropwise to a tetrahydrofuran solution (1 ml) of Compound 22 (21.6 mg), and the mixture was stirred at room temperature for 10 minutes. The reaction solution was poured into saturated ammonium chloride aqueous solution and extracted three times with ethyl acetate. The extract was dried with anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 16 mg of Compound 23.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.79-7.71 (4H, m), 7.03 (1H, dd, 11.2, 16.1 Hz), 6.77 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.04 (1H, dd, 10.5, 11.2 Hz), 5.39 (1H, dd, 3.2, 10.5 Hz), 5.26 (1H, m), 3.93 (2H, m), 3.84 (1H, d, 16.1 Hz), 3.73 (1H, d, 16.1 Hz), 3.62 (2H, m), 3.23 (1H, m), 2.91 (1H, m), 2.39 (1H, m), 1.80-1.33 (9H, m), 1.47 (3H, d, 6.8 Hz).  
FAB-MS m/z: 609 [M+H]<sup>+</sup>

## Example 24

## Compound 24:

5 O-(6-Azidoethyl)hydroxylamine hydrochloride (575 mg) was added to a pyridine solution (5 ml) of radicicol (900 mg), and the mixture was stirred at room temperature for 78 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 319 mg of Compound 24.

10  $^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  (ppm): 7.23 (1H, dd, 11.2, 16.1 Hz), 6.72 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.15 (1H, dd, 10.5, 11.2 Hz), 5.58 (1H, 3.4, 10.5 Hz), 5.30 (1H, m), 4.19-4.08 (2H, m), 3.91 (1H, d, 16.1 Hz), 3.81 (1H, d, 16.1 Hz), 3.34 (1H, m), 3.01 (1H, m), 2.42 (1H, m), 1.77-1.65 (2H, m), 1.62-1.56 (9H, m), 1.52 (3H, d, 6.6 Hz)  
FAB-MS  $m/z$ : 505  $[\text{M}+\text{H}]^+$

## 15 Example 25

## Compound 25:

20 O-[5-(Tert-butoxycarbonyl)pentyl]hydroxylamine hydrochloride (400 mg) was added to a pyridine solution (3 ml) of radicicol (364 mg), and the mixture was stirred at room temperature for 19 hours and then at 60°C for 2 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 316 mg of Compound 25.

25  $^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  (ppm): 7.23 (1H, dd, 11.3, 16.2 Hz), 6.71 (1H, dd, 16.2 Hz), 6.42 (1H, s), 6.15 (1H, dd, 10.3, 11.3 Hz), 5.58 (1H, dd, 3.4, 10.3 Hz), 5.30 (1H, m), 4.15-4.08 (2H, m), 3.91 (1H, d, 16.0 Hz), 3.81 (1H, d, 16.0 Hz), 3.33 (1H, m), 3.02 (1H, m), 2.42 (1H, m), 2.25-2.20 (2H, m), 1.75-1.34 (7H, m), 1.52 (3H, d, 6.5 Hz), 1.43 (9H, s)  
FAB-MS  $m/z$ : 550  $[\text{M}+\text{H}]^+$

## Example 26

30

## Compound 26:

O-[5-[[2-(Trimethylsilyl)ethyl]oxycarbonyl]pentyl]hydroxylamine hydrochloride (915 mg) was added to a pyridine solution (2 ml) of radicicol (800 mg), and the mixture was stirred at room temperature for 22 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 295 mg of Compound 26.

35  $^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  (ppm): 7.23 (1H, dd, 11.2, 16.1 Hz), 6.71 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.15 (1H, dd, 10.7, 11.2 Hz), 5.58 (1H, dd, 3.7, 10.7 Hz), 5.30 (1H, m), 4.19-4.13 (4H, m), 3.91 (1H, d, 16.1 Hz), 3.81 (1H, d, 16.1 Hz), 3.34 (1H, m), 3.01 (1H, m), 2.41 (1H, m), 2.33-2.29 (2H, m), 1.77-1.30 (7H, m), 1.52 (3H, d, 6.8 Hz), 1.00-0.95 (2H, m), 0.03 (9H, s)  
FAB-MS  $m/z$ : 594  $[\text{M}+\text{H}]^+$

## Example 27

45

## Compound 27:

O-[6-(Allyloxycarbonylamino)hexyl]hydroxylamine hydrochloride (116 mg) was added to a pyridine solution (3 ml) of radicicol (140 mg), and the mixture was stirred at room temperature for 79 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (1% methanol/chloroform) to obtain 156 mg of Compound 27.

55  $^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ )  $\delta$  (ppm): 7.23 (1H, dd, 11.2, 16.1 Hz), 6.71 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.15 (1H, t, 11.2 Hz), 5.91 (1H, m), 5.58 (1H, dd, 3.7, 11.2 Hz), 5.30 (1H, m), 5.27 (1H, dd, 1.7, 17.3 Hz), 5.16 (1H, br d, 10.5 Hz), 4.50 (2H, m), 4.18-4.06 (2H, m), 3.91 (1H, d, 16.1 Hz), 3.80 (1H, d, 16.1 Hz), 3.35 (1H, m), 3.12-3.07 (2H, m), 3.01 (1H, m), 2.41 (1H, m), 1.76-1.30 (9H, m), 1.52 (3H, d, 6.6 Hz)  
FAB-MS  $m/z$ : 563  $[\text{M}+\text{H}]^+$

## Example 28

## Compound 28:

6-Aminooxyhexanoic acid hydrochloride (270 mg) was added to a pyridine solution (2 ml) of radicicol (430 mg), and the mixture was stirred at room temperature for 12 hours and then at 60°C for 1 hour. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 213 mg of Compound 28.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.23 (1H, dd, 11.3, 16.2 Hz), 6.71 (1H, d, 16.2 Hz), 6.42 (1H, s), 6.15 (1H, dd, 10.8, 11.3 Hz), 5.58 (1H, dd, 3.6, 10.8 Hz), 5.30 (1H, m), 4.16-4.08 (2H, m), 3.91 (1H, d, 16.1 Hz), 3.80 (1H, d, 16.1 Hz), 3.33 (1H, m), 3.02 (1H, m), 2.42 (1H, m), 2.30 (2H, m), 1.77-1.45 (7H, m), 1.52 (3H, d, 6.5 Hz)  
FAB-MS m/z: 494 [M+H]<sup>+</sup>

## Example 29

## Compound 29:

Aminooxyacetic acid hemihydrochloride (1.0 g) was added to a pyridine solution (5 ml) of radicicol (1.5 g), and the mixture was stirred at room temperature for 20 hours and then at 60°C for 1.5 hours. The solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (2% methanol/chloroform) to obtain 692 mg of Compound 29.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.27 (1H, dd, 11.2, 16.1 Hz), 6.82 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.17 (1H, dd, 10.5, 11.2 Hz), 5.61 (1H, dd, 3.4, 10.5 Hz), 5.31 (1H, m), 4.64 (2H, m), 3.91 (1H, d, 16.4 Hz), 3.82 (1H, d, 16.4 Hz), 3.34 (1H, m), 3.02 (1H, m), 2.42 (1H, m), 1.60 (1H, ddd, 4.2, 9.0, 14.4 Hz), 1.53 (3H, d, 6.6 Hz)  
FAB-MS m/z: 438 [M+H]<sup>+</sup>

## Example 30

## Compound 30:

N-Hydroxysuccinimide (2.5 g) and 4-dimethylamino-pyridine (310 mg) were added in that order to a tetrahydrofuran solution (100 ml) of Compound 29 (5.2 g), the mixture was stirred for several minutes and then a tetrahydrofuran solution (30 ml) of dicyclohexylcarbodiimide (4.5 g) was added dropwise thereto at room temperature. After 2 hours of stirring at room temperature, the thus precipitated urea derivative was removed by filtration, and the resulting filtrate was concentrated under reduced pressure to obtain crude crystals of succinimide ester. The succinimide ester thus obtained was dissolved in 100 ml of dichloromethane and mixed with triethylamine (4.5 ml) and dimethylamine hydrochloride (2.0 g) in that order and then the mixture was stirred at room temperature. After 12 hours of the stirring, the reaction solvent was evaporated under reduced pressure, and the residue thus obtained was dissolved in ethyl acetate (500 ml), washed with 1 N hydrochloric acid aqueous solution and saturated sodium chloride aqueous solution and then dried with anhydrous sodium sulfate. This was purified by silica gel column chromatography (100 g; 2% methanol/chloroform) to obtain 2 g of Compound 30.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.27 (1H, dd, 11.3, 16.1 Hz), 6.81 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.17 (1H, dd, 10.5, 11.3 Hz), 5.61 (1H, dd, 3.5, 10.5 Hz), 5.30 (1H, m), 3.91 (1H, d, 16.1 Hz), 3.82 (1H, d, 16.1 Hz), 3.34 (1H, m), 3.08 (3H, s), 3.02 (1H, dd, 2.2, 3.7, 8.9 Hz), 2.95 (3H, s), 2.42 (1H, ddd, 3.6, 3.7, 14.5 Hz), 1.60 (1H, ddd, 4.1, 8.9, 14.5 Hz), 1.52 (3H, d, 6.6 Hz)  
FAB-MS m/z 465 [M+H]<sup>+</sup>

## Example 31

## Compound 31:

Radicicol (364 mg) and O-(3-hydroxypropyl)hydroxylamine hydrochloride (137 mg) were dissolved in 3 ml of pyridine and stirred at room temperature for 64 hours. The reaction solvent was evaporated under reduced pressure and then the resulting residue was purified by silica gel column chromatography (15 g; 1.5% methanol/chloroform) to obtain 186 mg of Compound 31.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 7.23 (1H, dd, 11.3, 16.1 Hz), 6.72 (1H, d, 16.1 Hz), 6.42 (1H, s), 6.15 (1H, dd, 10.6, 11.3 Hz), 5.59 (1H, dd, 3.5, 10.6 Hz), 5.30 (1H, m), 4.22 (2H, m), 3.91 (1H, d, 16.1 Hz), 3.80 (1H, d, 16.1 Hz), 3.67 (2H, m), 3.33 (1H, m), 3.01 (1H, m), 2.41 (1H, m), 1.92 (2H, m), 1.58 (1H, m), 1.52 (3H, d, 6.5 Hz)

FAB-MS m/z 438 [M+H]<sup>+</sup>

#### Example 32

##### Compound 32:

Triethylamine (0.2 ml) and 4-dimethylaminopyridine (78 mg) were added to a dichloromethane solution (6 ml) of Compound 9 (100 mg), and a tetrahydrofuran solution (2 ml) of palmitoyl chloride (0.2 ml) was added dropwise to the mixture which was cooled in an ice bath. This was stirred at 0°C for 1 hour and then at room temperature for 2 hours, subsequently evaporating the solvent under reduced pressure. The residue thus obtained was dissolved in diethyl ether, washed with saturated ammonium chloride aqueous solution, saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution and then purified by silica gel column chromatography (15 g; 20% ethyl acetate/hexane) to obtain 156 mg of Compound 32.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.09 (1H, dd, 11.3, 16.2 Hz), 6.98 (1H, s), 6.73 (1H, d, 16.2 Hz), 6.09 (1H, dd, 10.7, 11.3 Hz), 5.64 (1H, dd, 3.1, 10.7 Hz), 5.34 (1H, m), 4.02 (1H, d, 16.3 Hz), 3.96 (3H, s), 3.73 (1H, d, 16.3 Hz), 3.43 (1H, m), 2.97 (1H, m), 2.57 (2H, m), 2.46 (2H, m), 2.41 (1H, m), 1.77-1.59 (4H, m), 1.56 (3H, d, 6.5 Hz), 1.46-1.26 (48H, m), 0.88 (6H, t, 6.8 Hz)

FAB-MS m/z 870 [M+H]<sup>+</sup>

#### Example 33

##### Compound 33:

Two drops of concentrated hydrochloric acid (36%) was added to a dioxane solution (1.5 ml) of Compound 9 (33 mg), and the mixture was allowed to stand at room temperature for 30 minutes. The reaction solution was diluted with ethyl acetate (5 ml), washed twice with water and then dried with anhydrous sodium sulfate. This was purified by silica gel preparative thin layer chromatography (0.5 ml × 10 cm × 20 cm; chloroform/methanol-acetic acid, 194:5:1) to obtain 12 mg of Compound 33.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 6.66 (2H, m), 6.42 (1H, s), 6.10 (1H, m), 5.80 (1H, t, 10.3 Hz), 5.32 (1H, m), 4.97 (1H, dd, 3.4, 10.3 Hz), 4.59 (1H, d, 15.4 Hz), 3.89 (3H, s), 3.84 (1H, m), 3.67 (1H, d, 15.4 Hz), 2.09 (1H, m), 1.94 (1H, m), 1.45 (3H, d, 6.1 Hz)

FAB-MS m/z 430 [M+H]<sup>+</sup>

#### Example 34

##### Compound 34:

Using Compound 9 (22 mg), 8 mg of Compound 34 was obtained according to the procedure of Example 3.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 6.63 (2H, m), 6.42 (1H, s), 5.99 (1H, m), 5.93 (1H, t, 10.3 Hz), 5.31 (1H, m), 5.10 (1H, dd, 3.6, 10.3 Hz), 4.65 (1H, d, 15.7 Hz), 3.68 (1H, m), 3.67 (1H, d, 15.7 Hz), 2.03 (1H, m), 1.97 (1H, ddd, 3.6, 9.8, 14.4 Hz), 1.44 (3H, d, 6.0 Hz)

FAB-MS m/z 474, 476 [M+H]<sup>+</sup>

#### Example 35

##### Compound 35:

While cooling in an ice bath, 0.16 ml of oxalyl chloride was added dropwise to a dimethylformamide solution (7 ml) of Compound 9 (362 mg). This was stirred in the ice bath for 30 minutes and then at room temperature for 15 hours. The reaction solution was diluted with 50 ml of ethyl acetate, washed twice with water and then dried with anhydrous sodium sulfate. By carrying out purification with silica gel column chromatography (10 g; 2% methanol/chloroform), 94 mg of Compound 35 was obtained.



<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 8.10 (1H, s), 6.87 (1H, d, 16.0 Hz), 6.75 (1H, dd, 11.1, 16.0 Hz), 6.49 (1H, s), 6.19 (1H, t, 11.1 Hz), 5.58 (1H, t, 11.1 Hz), 5.45 (1H, m), 5.32 (1H, m), 5.27 (1H, dd, 4.5, 11.1 Hz), 3.91 (3H, s), 3.85 (1H, d, 15.9 Hz), 3.75 (1H, d, 15.9 Hz), 2.03 (1H, m), 1.95 (1H, dd, 4.8, 14.4 Hz), 1.51 (3H, d, 6.4 Hz)

FAB-MS m/z 458 [M+H]<sup>+</sup>

#### Example 36

##### Compound 36:

Using Compound 30 (410 mg), 188 mg of Compound 36 was obtained according to the procedure of Example 33.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ (ppm): 6.78 (1H, d, 16.0 Hz), 6.70 (1H, dd, 10.8, 16.0 Hz), 6.42 (1H, s), 6.10 (1H, dd, 10.8, 11.4 Hz), 5.82 (1H, t, 11.4 Hz), 5.33 (1H, m), 4.98 (1H, dd, 3.1, 11.4 Hz), 4.87-4.79 (2H, m), 4.61 (1H, d, 15.1 Hz), 3.84 (1H, m), 3.67 (1H, d, 15.1 Hz), 3.07 (3H, s), 2.95 (3H, s), 2.09 (1H, m), 1.93 (1H, m), 1.45 (3H, d, 6.0 Hz)

FAB-MS m/z 501 [M+H]<sup>+</sup>

#### Example 37

##### Tablets:

Compound 4 (50 g), lactose (40 g), corn starch (68 g) and carboxymethyl cellulose potassium (10 g) were mixed, and the mixture was kneaded by adding a 10% hydroxypropyl cellulose solution. The kneaded solution was applied to an extrusion granulating machine to make granules which were then mixed with magnesium stearate to obtain whole grain to be used as granules for tablet making use. This was applied to a tablet making machine in the usual way to obtain tablets containing 50 mg of Compound 4 in one tablet (170 mg).

#### Example 38

##### Capsules:

A mixture consisting of 30 g of Compound 4, 80 g of lactose and 58 g of potato starch was kneaded by adding a 10% hydroxypropyl cellulose solution. The kneaded solution was applied to an extrusion granulating machine to make granules which were then mixed with magnesium stearate and packed in hard capsules using an encapsulating machine to obtain capsules containing 30 mg of Compound 4 in one capsule (170 mg).

#### Example 39

##### Soft capsules:

Compound 4 (10 g) was dissolved in 100 g of soybean oil, and the solution thus obtained was injected into capsules in the usual way to prepare soft capsules containing 10 mg of Compound 4 in one capsule (110 mg).

#### Reference Example 1

##### 14,16-Dipalmitoylradicicol (Compound a):

A toluene solution (150 ml) of radicicol (5 g), pyridine (3.3 ml) and 4-dimethylaminopyridine (1.2 g) was cooled to 0°C, palmitoyl chloride (12.5 ml) was slowly added dropwise to the solution, and the resulting mixture was stirred at 0°C for 30 minutes. The reaction solution was diluted with chloroform (400 ml) and washed with dilute hydrochloric acid aqueous solution, saturated sodium bicarbonate aqueous solution and saturated brine. This was dried with anhydrous sodium sulfate and then purified by silica gel column chromatography (4:1 n-hexane/ethyl acetate) to obtain 12 g of Compound a.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm): 7.52 (1H, dd, 10.3, 16.1 Hz), 7.02 (1H, s), 6.15 (1H, t, 10.3 Hz), 6.06 (1H, d, 16.1 Hz), 5.79 (1H, dd, 3.9, 10.3 Hz), 5.40 (1H, m), 4.03 (1H, d, 16.4 Hz), 3.92 (1H, d, 16.4 Hz), 3.52 (1H, m), 3.02 (1H, ddd, 2.2, 2.2, 7.8 Hz), 2.58 (2H, t, 7.6 Hz), 2.49 (2H, ddd, 1.7, 7.3, 7.3 Hz), 2.40 (1H, 3.4, 3.4, 14.7 Hz), 1.78-1.60 (5H, m), 1.54 (3H, d, 6.6 Hz), 1.49-1.23 (48H, m), 0.88 (6H, t, 6.8 Hz).


FAB-MS m/z: 841 [M+H]<sup>+</sup>

## INDUSTRIAL APPLICABILITY

The radicicol derivative of the present invention can be used in pharmaceutical preparations which have antitumor, antibacterial or immunosuppression effects.

## Claims

1. A radicicol derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof:



wherein R<sup>1</sup> and R<sup>2</sup> are the same or different and each represents hydrogen, alkanoyl, alkenoyl or tert-butyl/dimethylsilyl;

(1)

when X represents halogen,


Y represents an oxygen atom or R<sup>4</sup>-O-N

{wherein R<sup>4</sup> represents hydrogen or substituted or unsubstituted lower alkyl

(said substituent is selected from hydroxyl, lower alkoxy, lower alkanoyloxy, azido, amino, mono- or di-lower alkylamino, lower alkanoylamino, lower alkoxy carbonylamino, lower alkenyloxy carbonylamino, carboxy, lower alkoxy carbonyl, lower alkyl carbamoyl and cyclic imido); and

R<sup>3</sup> represents hydrogen, alkanoyl, alkenoyl or -SO-Z

(wherein Z represents the following formula (A):



{wherein X<sup>A</sup>, R<sup>1A</sup> and R<sup>2A</sup> have the same meaning as X, R<sup>1</sup> and R<sup>2</sup>, respectively; and

Y<sup>A</sup> represents an oxygen atom or R<sup>4A</sup>-O-N

(wherein R<sup>4A</sup> has the same meaning as R<sup>4</sup>)};

and (2)

when X and R<sup>3</sup> are combined with each other to represent a single bond;

Y represents R<sup>4B</sup>-O-N

(wherein R<sup>4B</sup> has the same meaning as R<sup>4</sup>).

2. The compound according to claim 1, wherein X is halogen.

3. The compound according to claim 1, wherein Y is R<sup>4</sup>-O-N (wherein R<sup>4</sup> has the same meaning as defined above).

4. A therapeutic agent of diseases caused by tyrosine kinase, which contains at least one of the compounds according to any one of claims 1 to 3.

5

10

15

20

25

30

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/01158

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int. Cl <sup>6</sup> C07D313/00, C07D493/04, A61K31/365 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int. Cl <sup>6</sup> C07D313/00, C07D493/04, A61K31/365 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MO1. Gen. Genet., 236(2-3) (1993) p. 347-354	1 - 4
A	Cancer Res., 42(24) (1992) p. 6926-6930	1 - 4
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search July 22, 1996 (22. 07. 96)		Date of mailing of the international search report August 6, 1996 (06. 08. 96)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**